Skip to main content

Advertisement

ADVERTISEMENT

Commentary

Benefits of Cutting Balloon Before Stenting “Cut and Stent”

*Raoul Bonan, MD and †David Meerkin, MBBS
November 2003
Neointimal hyperplasic response following angioplasty (PTCA), and especially stent implantation, is linked to overstretch injury, causing modulation of the vascular cytoskeleton and subsequent production of mediators.1 These result in smooth muscle cell migration and replication, and production of extra cellular matrix.2–7 These processes associated with vascular remodeling or lack of adequate vascular compliance result in restenosis. Stents have been demonstrated to affect a larger post-angioplasty lumen.8,9 This results in reduced restenosis, in spite of an increased neointimal response when compared with balloon alone.10 New stent designs have emerged in an attempt to improve on the deficiencies of the first-generation stents such as excessive rigidity, articulation gaps and non-uniform expansion.11 The ability to adequately deploy a stent with fewer traumas to the vessel wall due to improved radial compliance may therefore result in reduced neointimal formation. Stents have been shown to reduce the incidence of restenosis.8,9 They prevent arterial recoil and negative or deleterious remodeling by offering a scaffolding (geometrical support) to keep the vessel open.10,12 However, they do cause some focal necrosis at the site of indentation into the media. Histological and IVUS studies suggest that stents induce a greater intimal proliferative response than PTCA alone.13 Thus, it was conjectured that cutting balloon (CB) induced controlled dissection prior to stent deployment would result in increased vascular radial compliance. This, in turn, could result in a decrease of strut-induced medial necrosis and the potential reduction of the stimulus for neointimal proliferation. This would also be coupled with the scaffolding benefits of the implanted stent. All stent designs have been shown to induce similar changes. However, recently stent versus stent trials have demonstrated that the newer generation stents tend to have less restenosis than the originally clinically approved stents.14 This may be design related, with the absence of a central articulation and greater compliance during balloon inflation deployment, resulting in better apposition with lower pressure inflations.11,15 CB can achieve scoring and full inflation at a pressure as low as 4 atmospheres, which can be effective for a non-compliant balloon, and we certainly miss the IVUS analysis right after this inflation to understand if the lesion was adequately prepare for stenting. No information about the stents used was given in the study; will different stents behave the same fashion after cutting balloon? The modification of the compliance engendered by the CB may transform the behavior delivery of the stents, which surely “were not created equal”. All “atherectomy devices” will generate some embolization —are we missing information about the timing of such embolization to point out the responsible: CB or stent — or lesion? In this issue of the Journal of Invasive Cardiology, Dr. Rizik and colleagues state: “The importance of the lower inflation pressures used to obtain luminal gains is underscored because of the surfeit of data, suggesting that higher inflation pressures potentially result in greater damage to the vessel wall. The reduced barotrauma to the vessel wall may eventually lead to lower restenosis rates”. We critically miss the relation with the long term and the restenosis. Finally, to understand the utility of “Cut and Stent”, we must come back to the MUSIC (or CRUISE)16,17 study to find out when the MUSIC criteria were fulfilled: at 8, 10 or 12 atmospheres? “Cut and Stent”, by improving the compliance of the vessel, may be extremely valuable now since more complex lesions will benefit from “drug-eluting stents”.
1. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Kinetics of cellular proliferation after arterial injury: Role of acute distension in the induction of growth muscle proliferation. Lab Invest 1989;60:360–364. 2. Gravanis MB, Roubin GS. Histopathologic phenomena at the site of percutaneous transluminal angioplasty: The problem of restenosis. Hum Pathol 1989;20:477–485. 3. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon angioplasty: A practical proliferative model on porcine coronary arteries. Circulation 1990;82:2190–2200. 4. Bonan R, Paiement P, Scortichini D, et al. Coronary restenosis: Evaluation of a restenosis injury index in a swine model. Am Heart J 1993;126:1334–1340. 5. Nobuyoshi M, Kimura T, Ohishi H, et. al. Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients. J Am Coll Cardiol 1991;17:443–449. 6. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267–274. 7. MacLeod DC, Strauss BH, de Jong M, et al. Proliferation and extracellular matrix synthesis of smooth muscle cell cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994;23:59–65. 8. Fischman D, Leon MB, Baim D, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496–501. 9. Serruys P, de Jaegere P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary disease. N Engl J Med 1994;331:489–495. 10. Hoffman R, Mintz GS, Dussaillant GR, et. al. Patterns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study. Circulation 1996;94:1247–1254. 11. Carrozza Jr. JP, Hermiller JB, Linnemeier TJ, et al. Quantitative coronary angiographic and intravascular ultrasound assessment of a new non-articulated stent: Report from the Advanced Cardiovascular Systems MultiLink stent pilot study. J Am Coll Cardiol 1998;31:50–56. 12. Painter JA, Mintz GS, Wong SC, et al. Serial intravascular ultrasound studies fail to show evidence of chronic Palmaz-Schatz stent recoil. Am J Cardiol 1995;75:1247–1254. 13. Schwartz RS. Characteristics of an ideal stent based upon restenosis pathology. J Invas Cardiol 1996;8:386–387. 14. De Schreder IK, Wilczek KL, Verbeken EV, et al. Biocompatibility of polymer coated oversized metallic stents implanted in normal porcine arteries. Atherosclerosis 1995;114:105–114. 15. Carter AJ, Laird JR, Kufs WM, et al. Coronary stenting with a novel stainless steel balloon-expandable stent: Determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. J Am Coll Cardiol 1996;27:120–127. 16. de Jaegere P, et al. MUSIC. Eur Heart J 1998;19:1122–1124. 17. Fitzgerald P, et al. CRUISE. Circulation 2000;102:523–530.

Advertisement

Advertisement

Advertisement